Gold prices edge higher on raised Fed rate cut hopes
MALVERN, Pa. - Ocugen, Inc. (NASDAQ:OCGN), a biotechnology company focused on gene therapies for blindness diseases, announced today it has secured a $20 million investment through a registered direct offering with Janus Henderson Investors. The company, currently valued at $292 million, has been actively seeking funding as InvestingPro data shows an EBITDA of -$52.3 million in the last twelve months.
The agreement includes the sale of 20 million shares of common stock and warrants to purchase up to an additional 20 million shares at a purchase price of $1.00 per share and accompanying warrant. The warrants have an exercise price of $1.50 per share, are immediately exercisable, and will expire two years after issuance. According to InvestingPro analysis, the stock has shown strong momentum with a 40% gain over the past six months, though analysts maintain price targets ranging from $4 to $8 per share.
If the warrants are fully exercised, Ocugen could receive up to an additional $30 million in gross proceeds. The company noted the warrants are callable when the volume-weighted average price of its common stock exceeds $2.50 per share for at least five days within a 30-trading-day period.
Noble Capital Markets, Inc. is acting as the sole placement agent for the offering, which is expected to close on or about August 11, subject to customary closing conditions.
The offering is being conducted under an effective shelf registration statement previously filed with the Securities and Exchange Commission.
Ocugen describes itself as developing a modifier gene therapy platform aimed at addressing blindness diseases including retinitis pigmentosa, Stargardt disease, and geographic atrophy, a late-stage form of dry age-related macular degeneration. InvestingPro subscribers can access 12 additional key insights about Ocugen’s financial health and market position through the comprehensive Pro Research Report, available exclusively on the platform.
The announcement was made in a press release statement issued by the company.
In other recent news, Ocugen, Inc. announced its Q2 2025 earnings, revealing a modest improvement over analyst expectations. The company reported an earnings per share (EPS) of -$0.05, slightly better than the anticipated -$0.06, resulting in a 16.67% positive surprise. Revenue for the quarter amounted to $1.37 million. These earnings results are part of the company’s ongoing financial disclosures. There were no updates on any mergers or acquisitions involving Ocugen during this period. Analyst firms have not made any recent upgrades or downgrades for Ocugen’s stock. Investors continue to monitor Ocugen’s financial performance closely. These developments are part of the recent updates concerning Ocugen’s business activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.